ORPHA:699697
Necrotizing fasciitis
Publications
13,892
Trials
8
Interventional, condition-specific
Researchers
916
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
13,892 matched papers (8,072 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
8 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
13,892
13,892 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
13,892 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,072 in the last 10 years · low confidence
Phrase hits: 13,892 · MeSH hits: 0
Who's working on it?
916
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li X6 papers · 2026
Department of Plastic and Cosmetic surgery and Burns, Qilu Hospital of Shandong University, Jinan, China.
Papers in Europe PMC - 02Wang X6 papers · 2026
Department of Hematology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University Tianjin 300121, China.
Papers in Europe PMC - 03Wang L4 papers · 2026
Department of Medical, Southeast University, 87 Dingjiaqiao street, Nanjing, Jiangsu Province, China.
Papers in Europe PMC - 04Chen Z3 papers · 2026
Department of Colorectal Surgery, Nanjing Hosipital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Daming Road, Qin Huai District, Nanjing, Jiangsu, 210022, China.
Papers in Europe PMC - 05Fukushima S3 papers · 2026
Department of Infectious Diseases, Okayama University Hospital, Japan.
Papers in Europe PMC - 06Hagiya H3 papers · 2026
Department of Infectious Diseases, Okayama University Hospital, Japan.
Papers in Europe PMC - 07Li W3 papers · 2026
Department of Dermatology, Peking University Third Hospital, Haidian District, Beijing.
Papers in Europe PMC - 08Li Y3 papers · 2026
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Papers in Europe PMC - 09Liu Y3 papers · 2026
Department of Endocrinology, Peking University Third Hospital, Haidian District, Beijing.
Papers in Europe PMC - 10Rothstein JL3 papers · 2026Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
8 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 91.5th percentile).
low confidence · 91.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07170020·NOT YET RECRUITING·Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections
Not reviewed·Conditions: Necrotizing Fascitis·Matched via name phrase
Observational and natural-history studies
11 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- ctis·2024-510941-32-00·Authorised, ongoing·DAPA-ICU Trial - Dapagliflozin for cardio-renal protection after ICU discharge. A prospective, randomized, double blinded, multicenter study
skipped — LLM skipped (--skip-llm)
- ctis·2023-506981-30-00·Cancelled·(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15245496·No longer recruiting·Use of intravenous and oral antibiotics for the treatment of skin and soft-tissue infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76443564·No longer recruiting·The efficacy and safety evaluation of ceftriaxone and sulbactam combination (1.5 gram) in patients with skin and soft tissue infections: an open label, parallel, randomized, prospective comparative trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Necrotizing fasciitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Necrotizing fasciitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Necrotizing fasciitis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 11 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-27T20:52:15.089Z